{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:53:40Z","timestamp":1791118420225,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,7,17]],"date-time":"2008-07-17T00:00:00Z","timestamp":1216252800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s00277-008-0539-z","type":"journal-article","created":{"date-parts":[[2008,7,16]],"date-time":"2008-07-16T18:19:11Z","timestamp":1216232351000},"page":"985-990","source":"Crossref","is-referenced-by-count":13,"title":["The expression and prognostic significance of platelet-derived growth factor receptor alpha in mature T- and natural killer-cell lymphomas"],"prefix":"10.1007","volume":"87","author":[{"given":"Ya-Ping","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kung-Chao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Chou","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,7,17]]},"reference":[{"key":"539_CR1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1200\/JCO.1989.7.6.725","volume":"7","author":"AL Cheng","year":"1989","unstructured":"Cheng AL, Chen YC, Wang CH, Su IJ, Hsieh HC, Chang JY et al (1989) Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades\u2014should peripheral T-cell lymphoma be considered separately? J Clin Oncol 7:725\u2013731","journal-title":"J Clin Oncol"},{"key":"539_CR2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1046\/j.1440-1827.2000.01108.x","volume":"50","author":"Lymphoma Study Group of Japanese Pathologists","year":"2000","unstructured":"Lymphoma Study Group of Japanese Pathologists (2000) The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 50:696\u2013702 doi: 10.1046\/j.1440-1827.2000.01108.x","journal-title":"Pathol Int"},{"key":"539_CR3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","volume":"13","author":"T Rudiger","year":"2002","unstructured":"Rudiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Non-Hodgkin\u2019s Lymphoma Classification Project et al (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 13:140\u2013149 doi: 10.1093\/annonc\/mdf033","journal-title":"Ann Oncol"},{"key":"539_CR4","first-page":"76","volume":"92","author":"C Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Bri\u00e8re J, Haioun C et al (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA). Blood 92:76\u201382","journal-title":"Blood"},{"key":"539_CR5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","volume":"9","author":"A Lopez-Guillermo","year":"1998","unstructured":"Lopez-Guillermo A, Cid J, Salar A, L\u00f3pez A, Montalb\u00e1n C, Castrillo JM et al (1998) Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 9:849\u2013855 doi: 10.1023\/A:1008418727472","journal-title":"Ann Oncol"},{"key":"539_CR6","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4065\/81.9.1241","volume":"81","author":"RH Alvarez","year":"2006","unstructured":"Alvarez RH, Kantarjian HM, Cortes JE (2006) Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 81:1241\u20131257","journal-title":"Mayo Clin Proc"},{"key":"539_CR7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","volume":"79","author":"CH Heldin","year":"1999","unstructured":"Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283\u20131316","journal-title":"Physiol Rev"},{"key":"539_CR8","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1016\/S0021-9258(18)98348-1","volume":"268","author":"MA Heidaran","year":"1993","unstructured":"Heidaran MA, Beeler JF, Yu JC, Ishibashi T, LaRochelle WJ, Pierce JH et al (1993) Differences in substrate specificities of alpha and beta platelet-derived growth factor (PDGF) receptors. Correlation with their ability to mediate PDGF transforming functions. J Biol Chem 268:9287\u20139295","journal-title":"J Biol Chem"},{"key":"539_CR9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1006\/bbrc.1994.2505","volume":"204","author":"A Uren","year":"1994","unstructured":"Uren A, Yu JC, Gholami NS, Pierce JH, Heidaran MA (1994) The alpha PDGFR tyrosine kinase mediates locomotion of two different cell types through chemotaxis and chemokinesis. Biochem Biophys Res Commun 204:628\u2013634 doi: 10.1006\/bbrc.1994.2505","journal-title":"Biochem Biophys Res Commun"},{"key":"539_CR10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1006\/bbrc.2001.4622","volume":"282","author":"J Yu","year":"2001","unstructured":"Yu J, Moon A, Kim HR (2001) Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration. Biochem Biophys Res Commun 282:697\u2013700 doi: 10.1006\/bbrc.2001.4622","journal-title":"Biochem Biophys Res Commun"},{"key":"539_CR11","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1126\/science.7701324","volume":"267","author":"R Yao","year":"1995","unstructured":"Yao R, Cooper GM (1995) Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267:2003\u20132006 doi: 10.1126\/science.7701324","journal-title":"Science"},{"key":"539_CR12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cytogfr.2004.03.004","volume":"15","author":"EW Raines","year":"2004","unstructured":"Raines EW (2004) PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15:237\u2013254 doi: 10.1016\/j.cytogfr.2004.03.004","journal-title":"Cytokine Growth Factor Rev"},{"key":"539_CR13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cytogfr.2004.03.006","volume":"15","author":"JC Bonner","year":"2004","unstructured":"Bonner JC (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15:255\u2013273 doi: 10.1016\/j.cytogfr.2004.03.006","journal-title":"Cytokine Growth Factor Rev"},{"key":"539_CR14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1535-6108(03)00089-8","volume":"3","author":"K Pietras","year":"2003","unstructured":"Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A (2003) PDGF receptors as cancer drug targets. Cancer Cell 3:439\u2013443 doi: 10.1016\/S1535-6108(03)00089-8","journal-title":"Cancer Cell"},{"key":"539_CR15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11912-007-0003-6","volume":"9","author":"NL Lewis","year":"2007","unstructured":"Lewis NL (2007) The platelet-derived growth factor receptor as a therapeutic target. Curr Oncol Rep 9:89\u201395 doi: 10.1007\/s11912-007-0003-6","journal-title":"Curr Oncol Rep"},{"key":"539_CR16","first-page":"3034","volume":"8","author":"R Dagher","year":"2002","unstructured":"Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G et al (2002) Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034\u20133038","journal-title":"Clin Cancer Res"},{"key":"539_CR17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","volume":"362","author":"A Pardanani","year":"2003","unstructured":"Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC et al (2003) Imatinib for systemic mast-cell disease. Lancet 362:535\u2013536 doi: 10.1016\/S0140-6736(03)14115-3","journal-title":"Lancet"},{"key":"539_CR18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S1470-2045(05)70213-8","volume":"6","author":"PP Piccaluga","year":"2005","unstructured":"Piccaluga PP, Agostinelli C, Zinzani PL, Baccarani M, Dalla Favera R, Pileri SA (2005) Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. Lancet Oncol 6:440 doi: 10.1016\/S1470-2045(05)70213-8","journal-title":"Lancet Oncol"},{"key":"539_CR19","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P et al (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23:5357\u20135364 doi: 10.1200\/JCO.2005.14.068","journal-title":"J Clin Oncol"},{"key":"539_CR20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708\u2013710 doi: 10.1126\/science.1079666","journal-title":"Science"},{"key":"539_CR21","first-page":"339","volume":"32","author":"RE Brown","year":"2002","unstructured":"Brown RE, Nazmi RK (2002) The Reed-Steinberg cell: molecular characterization by proteomic analysis with therapeutic implications. Ann Clin Lab Sci 32:339\u2013351","journal-title":"Ann Clin Lab Sci"},{"key":"539_CR22","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1182\/blood-2004-10-4008","volume":"105","author":"C Renne","year":"2005","unstructured":"Renne C, Willenbrock K, Kuppers R, Hansmann ML, Br\u00e4uninger A (2005) Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood 105:4051\u20134059 doi: 10.1182\/blood-2004-10-4008","journal-title":"Blood"},{"key":"539_CR23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11060-005-9102-0","volume":"79","author":"K Karabatsou","year":"2006","unstructured":"Karabatsou K, Pal P, Dodd S, Mat A, Haylock B, Aguirreburualde M et al (2006) Expression of survivin, platelet-derived growth factor A (PDGF-A) and PDGF receptor alpha in primary central nervous system lymphoma. J Neuro-Oncol 79:171\u2013179 doi: 10.1007\/s11060-005-9102-0","journal-title":"J Neuro-Oncol"},{"key":"539_CR24","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1172\/JCI26833","volume":"117","author":"PP Piccaluga","year":"2007","unstructured":"Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S et al (2007) Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 117:823\u2013834 doi: 10.1172\/JCI26833","journal-title":"J Clin Invest"},{"key":"539_CR25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/asheducation-2006.1.317","volume":"2006","author":"ES Jaffe","year":"2006","unstructured":"Jaffe ES (2006) Pathobiology of peripheral T-cell lymphomas. Hematology (Am Soc Hematol Educ Program) 2006:317\u2013322 doi: 10.1182\/asheducation-2006.1.317","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"539_CR26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF00206767","volume":"85","author":"RG Gronwald","year":"1990","unstructured":"Gronwald RG, Adler DA, Kelly JD, Disteche CM, Bowen-Pope DF (1990) The human PDGF receptor alpha-subunit gene maps to chromosome 4 in close proximity to c-kit. Hum Genet 85:383\u2013385 doi: 10.1007\/BF00206767","journal-title":"Hum Genet"},{"key":"539_CR27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1006\/geno.1995.9883","volume":"30","author":"J Kawagishi","year":"1995","unstructured":"Kawagishi J, Kumabe T, Yoshimoto T, Yamamoto T (1995) Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. Genomics 30:224\u2013232 doi: 10.1006\/geno.1995.9883","journal-title":"Genomics"},{"key":"539_CR28","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/sj.onc.1209232","volume":"25","author":"D Matei","year":"2006","unstructured":"Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C et al (2006) Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 25:2060\u20132069 doi: 10.1038\/sj.onc.1209232","journal-title":"Oncogene"},{"key":"539_CR29","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2559.2007.02634.x","volume":"50","author":"B Liegl","year":"2007","unstructured":"Liegl B, Gully C, Reich O, Nogales FF, Beham A, Regauer S (2007) Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations. Histopathology 50:448\u2013452 doi: 10.1111\/j.1365-2559.2007.02634.x","journal-title":"Histopathology"},{"key":"539_CR30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493\u2013502 doi: 10.1038\/nrd839","journal-title":"Nat Rev Drug Discov"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0539-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-008-0539-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0539-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T05:13:49Z","timestamp":1631510029000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-008-0539-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,17]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["539"],"URL":"https:\/\/doi.org\/10.1007\/s00277-008-0539-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,17]]}}}